DiaMedica Therapeutics
DMAC
11 hedge funds and large institutions have $4.6M invested in DiaMedica Therapeutics in 2019 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 4 closing their positions.
53% more capital invested
Capital invested by funds: $3M → $4.6M (+$1.6M)
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
22% more funds holding
Funds holding: 9 → 11 (+2)
0.18% less ownership
Funds ownership: 8.65% → 8.47% (-0.18%)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$902K |
| 2 |
BlackRock
New York
|
+$37.6K |
| 3 |
PFGIA
Patriot Financial Group Insurance Agency
Westborough,
Massachusetts
|
+$10.8K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$5.15K |
| 5 |
CHP
Cable Hill Partners
Portland,
Oregon
|
+$3.61K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GIPM
G2 Investment Partners Management
New York
|
-$640K |
| 2 |
MHP
Manatuck Hill Partners
Westport,
Connecticut
|
-$175K |
| 3 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$36.1K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$17K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$4K |
DMAC Hedge Fund Activity: Q1 2019 in Review
11 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in DiaMedica Therapeutics (DMAC) for Q1 2019, worth a combined $4.6M — up 53% from $3M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new DMAC positions and 4 closed out — a net gain of 2 holders — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Stonepine Capital Management, opening a new position worth an estimated $902K. The largest seller was G2 Investment Partners Management, exiting entirely with an estimated $640K sold.
- 11 institutional investors held DiaMedica Therapeutics (DMAC) as of Q1 2019, up from 9 in Q4 2018.
- Funds reported $4.6M of DiaMedica Therapeutics stock for Q1 2019, up 53% quarter-over-quarter.
- 6 funds opened new DiaMedica Therapeutics positions in Q1 2019 and 4 closed out, a net change of +2 holders.
- The largest DiaMedica Therapeutics buyer in Q1 2019 was Stonepine Capital Management, an estimated $902K added.
- The largest DiaMedica Therapeutics seller in Q1 2019 was G2 Investment Partners Management, an estimated $640K sold.
Based on aggregated 13F filings for Q1 2019.